CSF NfL and the p-tau/Aβ42 ratio are reported to be the only biomarkers to significantly differentiate DS with mild cognitive impairment (DS-MCI) from control participants in a small pilot study [43]. The gene discussed is NEFL; the disease is Dravet syndrome.